Potential Immunotherapy, Bria-IMT, Seen to Reduce Metastasis in Advanced Breast Cancer Patients in Trial

Potential Immunotherapy, Bria-IMT, Seen to Reduce Metastasis in Advanced Breast Cancer Patients in Trial
BriaCell Therapeutics' immunotherapy candidate Bria-IMT was found to be safe and well-tolerated, and significantly reduced the size of metastasis in two of the six breast cancer patients treated in a Phase 1/2 study, early trial data show. These results will be shared in the presentation, “SV-BR-1-GM a whole-cell targeted immunotherapy for breast cancer: Preliminary clinical data,” part of the the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, running from June 1-5 in Chicago. Bria-IMT, also called SV-BR-1-GM, is a potential immunotherapy made of a breast tumor cell line engineered to release a factor – called granulocyte-macrophage colony-stimulating factor (GM-CSF) – that activates the immune system with a goal of  increasing its ability to recognize and kill tumor cells. The therapy is given via an intra-dermal (skin) injection. The cells in the therapy are unable to replicate inside the body. Data from a Phase 1 pilot study (NCT00095862), showed that patients with stage 4 breast cancer experienced substantial regression of breast, lung, and brain metastasis following Bria-IMT injection, in addition to treatment with cyclophosphamide chemotherapy and interferon alfa. The ongoing Phase 1/2 study (NCT03066947) is a single-arm, open-label study\to evaluate Bria-IMT’s safety when injected into patients with recurrent and/or metastatic breast cancer. Additional – secondary – outcomes include the treatm
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.